Sirona Dx
Sirona Dx is a CLIA/GCLP-accredited technical CRO founded in 2016 in Portland, Oregon, providing spatial biology and single-cell multi-omics services to 30+ pharmaceutical and biotechnology clients developing immunotherapies and targeted therapies. It operates a multi-platform laboratory spanning Imaging Mass Cytometry, CyTOF, CODEX, COMET, and CosMx with custom assay development, bioinformatics, and AI-driven analytics partnerships.
- Company typePrivate
- Founded2016
- HeadquartersPortland, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Sirona Dx does
Sirona Dx is a privately held, CLIA- and GCLP-accredited technical contract research organization (CRO) founded in 2016 and headquartered in a single Portland, Oregon laboratory (4640 SW Macadam Avenue). It is purpose-built to serve pharmaceutical and biotechnology sponsors developing immunotherapies and targeted therapies, providing specialized single-cell proteomics, transcriptomics, and spatial biology services from exploratory biomarker discovery through clinical trial laboratory support. The company serves 30 or more pharma and biotech clients with a consultative, enterprise sales motion that spans platform selection, custom panel design, assay optimization, validation, and bioinformatics analysis.
The company's core technology stack is platform-agnostic and multi-vendor, integrating Imaging Mass Cytometry (Fluidigm Hyperion), CyTOF mass cytometry, Akoya CODEX, Lunaphore COMET, NanoString CosMx and nCounter, Cytek full spectrum flow cytometry, Olink proximity extension assays, and Hamamatsu MoxiePlex imaging. Sirona Dx layers proprietary assay IP on top of these platforms, most notably a 34-marker Human Immune Portrait TME Panel for tumor microenvironment profiling and custom CyTOF panels reaching up to 45 markers. It augments wet-lab capabilities with AI-driven analytics via partnerships with PredxBio (SpaceIQ), Nucleai, and Scailyte (ScaiVision), and provides in-house bioinformatics and digital image analysis.
The business model is straightforward professional services: revenue is generated through contracted laboratory and analysis engagements with pharma, biotech, and academic medical center sponsors, priced via contact-based quoting rather than published rates. Marketing relies on technical content, conference presence (e.g., AACR booth #3442), press release distribution, and a science portal. The company was awarded Medhealth Outlook's "Top 10 CRO of 2021," and has established strategic alliances with most leading spatial biology platform developers, positioning it as a category-leading specialty CRO for immunotherapy biomarker programs.
Sirona Dx firmographics
Firmographics- Name
- Sirona Dx
- Legal name
- Sirona Dx
- Website
- https://sironadx.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Sirona Dx is a CLIA/GCLP-accredited technical CRO founded in 2016 in Portland, Oregon, providing spatial biology and single-cell multi-omics services to 30+ pharmaceutical and biotechnology clients developing immunotherapies and targeted therapies. It operates a multi-platform laboratory spanning Imaging Mass Cytometry, CyTOF, CODEX, COMET, and CosMx with custom assay development, bioinformatics, and AI-driven analytics partnerships.
- Ownership category
- akta.pro rank
Sirona Dx industry classification
Industry- Product category
- Contract Research Services — Spatial Biology & Multi-Omics
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)
- akta.pro secondary industries
- Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where Sirona Dx is headquartered
LocationHeadquarters
- HQ city
- Portland
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sirona Dx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: Sirona Dx operates as a technical CRO providing specialized laboratory services to pharmaceutical and biotech companies. Revenue is generated through service contracts for single cell multi-omics, spatial biology, and biomarker analysis services. From exploratory biomarker development through to clinical trial support, services are provided across the drug development continuum.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Sirona Dx product offering
Product offeringCore offering
Sirona Dx is a technical Contract Research Organization that provides spatial biology and single cell multi-omics laboratory services to pharmaceutical and biotechnology companies developing immuno-oncology and immune-based therapeutics. Its offerings span CyTOF/mass cytometry, imaging mass cytometry, multiplex immunofluorescence, spatial transcriptomics, histopathology and immune profiling, delivered through a CLIA/GCLP-accredited laboratory supported by bioinformatics analysis.
Product overview
Sirona Dx is a technical CRO founded in 2016, offering specialized single cell multi-omics and spatial biology services within a GCLP and CLIA accredited laboratory. The company's service portfolio centers on spatial biology platforms (including Nanostring CosMx, Fluidigm Hyperion/Imaging Mass Cytometry, Lunaphore COMET, and Akoya CODEX), CyTOF/mass cytometry for ultra-deep immunophenotyping up to 45 markers, Cytek full spectrum flow cytometry, and bulk cell analysis including Olink protein detection and NanoString nCounter gene expression. Core services include immune profiling, imaging mass cytometry, histopathology, IO expression assays, and advanced bioinformatics for digital image analysis and spatial data interpretation. Partnerships augment capabilities with AI-powered analytics platforms including PredxBio SpaceIQ, Nucleai, and Scailyte ScaiVision for biomarker discovery and predictive analytics.
Differentiator
Problem solved
Functional benefit
Brands
- Human Immune Portrait TME Panel: A 34-marker highly optimized IMC panel enabling comprehensive analysis of the tumor microenvironment at sub-cellular resolution.
Products and services
- Spatial Biology Services CRO service that characterizes tissue samples using spatial biology platforms to map cellular phenotypes and biomarker localization, supporting translational research for pharma and biotech sponsors.
- CyTOF / Mass Cytometry Services Fee-for-service high-parameter suspension mass cytometry using CyTOF instrumentation, enabling deep immune-phenotyping of cell populations from client-supplied samples.
- Imaging Mass Cytometry Services Tissue-based multiplexed antibody imaging service using Imaging Mass Cytometry, allowing highly multiplexed spatial phenotyping of solid tumor and tissue specimens.
- Multiplex Immunofluorescence Services Multiplex fluorescence-based tissue phenotyping service for simultaneous detection of multiple immune and tumor markers in formalin-fixed specimens.
- Immune Profiling Services Phenotypic and functional characterization of immune cell populations using multi-omics assays to support immunotherapy and cell-therapy development.
- IO Expression Assays Immuno-oncology focused expression-based assays measuring immune-checkpoint and immune-signature biomarkers, available as a service offering for sponsors.
- Histopathology Services Tissue processing, staining (including IHC and multiplexed IF) and histopathology read-outs delivered within a CLIA/GCLP-accredited laboratory environment.
- Bioinformatics and Data Analysis Services Downstream analytics, including image segmentation, cell phenotyping, clustering and biomarker interpretation, delivered alongside Sirona Dx's laboratory assays.
Quantifiable outcome
- Highly optimized 34 marker Immune Portrait TME Panel for comprehensive tumor microenvironment analysis at sub-cellular resolution
- +3 more outcomes
Companies that use Sirona Dx
Customer profileSegments3 records
Ideal customer profiles3 records
Sirona Dx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Sirona Dx partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and key.
- NucleaicoreStrategic partnership to deliver integrated spatial proteomics solution for pharmaceutical companies. Sirona Dx leads assay design, development and validation while Nucleai provides AI-powered spatial analytics from feature extraction through biomarker discovery. Delivers seamless end-to-end solution from tissue data to biological insight for pharma sponsors.
- Hamamatsu PhotonicscoreSirona Dx named as Technology Access Partner for Hamamatsu's MoxiePlex spatial proteomics technology. Partnership streamlines technology evaluation by providing customers access to spatial biology expertise within GCLP/CLIA accredited laboratory. Removes barriers to adoption through expertise in sample preparation, staining, imaging and bioinformatics analysis.
- PredxBiocoreStrategic partnership leveraging Explainable AI-Driven Spatial Biology with SpaceIQ platform to unlock potential of genomic, proteomic and transcriptomic data. Sirona Dx serves as CRO partner facilitating deployment of Explainable AI-based diagnostic algorithms. Combined capabilities aim to identify novel spatial signatures in high-plex assays predicting therapy responses.
- NanoString TechnologieskeyIntegrated CosMx spatial molecular imaging platform. NanoString partners with Sirona Dx along with Macrogen and Propath to accelerate access to spatial biology capabilities for biopharma companies globally.
- LunaphorecoreSirona Dx became first US-based CRO to offer Lunaphore's COMET spatial biology platform as a service. COMET provides fully automated, high-throughput hyperplex tissue profiling with 40 markers per run. Partnership complements Sirona Dx's spatial-omics operations with off-the-shelf, label-free primary antibody compatibility.
- ScailytekeyStrategic partnership creating biomarker discovery engine combining Sirona Dx laboratory workflow solutions with Scailyte's AI-driven data analytics platform ScaiVision. Focus on oncology and immunology applications including patient qualification, stratification for clinical trials, and advanced therapy development.
- UltivuekeyCo-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions. Ultivue's InSituPlex technology (up to 12-plex) complements Sirona Dx's high-parameter capabilities. Joint offering provides seamless workflow for biomarker discovery and drug development.
- Akoya BiosciencescoreAdded CODEX ultra-high plex imaging platform to service offerings. Allows imaging of 40+ protein biomarkers across whole tissue sections. Provides multidimensional phenotypic maps of tumor microenvironment with single-cell resolution while maintaining spatial context.
- Fluidigm (Standard BioTools)coreSirona Dx launched Imaging Mass Cytometry services on Fluidigm Hyperion Imaging System. First Imaging Mass Cytometry CRO partner in the United States. Enables simultaneous imaging of up to 37 protein markers at subcellular resolution for biomarker discovery.
- IncellDxkeyLaunched Oncocyst PD-L1 assay using IncellDx technology for bladder cancer detection. Detects and quantifies abnormal bladder cells and immune cells expressing PD-L1 from urine cytology specimens using multi-parameter flow cytometry and bioinformatics.
- Thermo Fisher ScientifickeyAdopted Thermo Fisher's Oncomine Focus Assay to run on Ion PGM System. Expands drug development and NGS services with 52 solid tumor genes associated with current oncology therapies.
- OlinkkeySirona Dx is an Olink Certified Service Provider using Olink technology for simultaneous measurement of hundreds of protein biomarkers from minimal sample volumes with exceptional sensitivity and specificity.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Sirona Dx competitors and assessment
Company assessmentBroad incumbents
- ICON plc: Top-five global CRO with laboratory services and biomarker capabilities supporting clinical development. Comparable as a large-scale clinical trial services competitor; less specialized in spatial biology than Sirona Dx.
- Q² Solutions: Joint venture central laboratory and biomarker services provider serving global clinical trials with flow cytometry, genomics, and immunoassay capabilities. Comparable as a clinical-trial-grade lab services competitor with overlapping biomarker offerings.
- Eurofins Scientific: Global lab services conglomerate with extensive pharma services including biomarker, genomic, and specialty assay work. Comparable as a scale player in pharma lab services with significant overlap in customer base, though Eurofins' reach is far broader.
- Labcorp Drug Development: One of the largest global CROs with central laboratory, biomarker, and specialty testing services including flow cytometry and genomic profiling. Competes with Sirona Dx for pharma biomarker contracts, though Labcorp's portfolio is far broader and lacks Sirona's pure-play spatial biology focus.
- NeoGenomics Laboratories: Clinical oncology-focused lab services company with growing pharma services division offering spatial biology and molecular profiling. Competes with Sirona Dx for biomarker work but operates at substantially larger scale and serves clinical diagnostics customers as well.
- Charles River Laboratories: Major CRO with discovery, safety assessment, and specialty lab services including biomarker and cell-based assay work. Comparable customer overlap with Sirona Dx but a much broader services portfolio and global footprint.
Direct peers
- BioAgilytix Labs: Specialized bioanalytical and biomarker CRO with deep large-molecule, immunoassay, and cell-based assay expertise serving global biopharma. Highly comparable to Sirona Dx as a focused, science-led CRO competing for biomarker and immuno-oncology work, though BioAgilytix is much larger and broader in scope.
- Precision for Medicine: Precision medicine-focused CRO with biomarker, immuno-oncology, and companion diagnostic development capabilities for biopharma. Comparable as a specialized services provider targeting the same pharma translational and clinical trial customer set.
- CellCarta (formerly Caprion): Specialized immunology and single-cell flow cytometry/mass cytometry CRO serving pharma biomarker discovery and clinical trials. Most directly comparable peer given its positioning as a premium scientific CRO focused on immune monitoring and multiplexed proteomics.
Emerging players
- 10x Genomics: Leading single-cell and spatial biology platform vendor (Chromium, Visium, Xenium) whose services partner ecosystem and direct-to-pharma support competes for the same single-cell/spatial work Sirona Dx services. Treated as an emerging player in services given its primary identity as a tool vendor, but increasingly adjacent to Sirona's offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Sirona Dx social profiles
Digital presenceSirona Dx compliance and trust
Trust signalCompliance3 records
Sirona Dx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sirona Dx leadership team
Management profileNumber of profiles
Profiles13 records
Sirona Dx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sirona Dx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sirona Dx
What does Sirona Dx do?
Sirona Dx is a technical Contract Research Organization that provides spatial biology and single cell multi-omics laboratory services to pharmaceutical and biotechnology companies developing immuno-oncology and immune-based therapeutics. Its offerings span CyTOF/mass cytometry, imaging mass cytometry, multiplex immunofluorescence, spatial transcriptomics, histopathology and immune profiling, delivered through a CLIA/GCLP-accredited laboratory supported by bioinformatics analysis.
Is Sirona Dx a public or private company?
Sirona Dx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Sirona Dx founded?
Sirona Dx was founded in 2016. It employs 11 to 50 people.
Where is Sirona Dx based?
Sirona Dx is headquartered in Portland, United States, in the North America region.
How does Sirona Dx make money?
One revenue line is on record: contract Research Services.
Who are Sirona Dx's main competitors?
Broad incumbents on record are ICON plc, Q² Solutions, Eurofins Scientific, Labcorp Drug Development, NeoGenomics Laboratories and Charles River Laboratories. Direct peers are BioAgilytix Labs, Precision for Medicine and CellCarta (formerly Caprion). 10x Genomics is listed as an emerging player.
Does Sirona Dx have an API?
No public API is recorded for Sirona Dx.
What industry is Sirona Dx in?
Sirona Dx's product category is Contract Research Services — Spatial Biology & Multi-Omics. Its primary akta.pro industry code is HLAGAEAJ, Companion Diagnostics (CDx) Development & Trial Testing Support, with a secondary code of HLAAALAF, Companion Diagnostics (CDx) & Therapy Selection Assays. Its NAICS code is 621511 and its SIC code is 8071.